MedTrace Logo

A Study of KY1005 in Healthy Volunteers

NCT03161288 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2019-08-29

No results posted yet for this study

Summary

This is a single and multiple ascending dose, placebo-controlled, double-blind, Phase 1 study to evaluate the safety and tolerability of KY1005 in healthy volunteers.

Conditions

  • Immune System Diseases

Interventions

DRUG

KY1005

A human anti-OX40 ligand monoclonal antibody

DRUG

Placebo

Matched placebo

Sponsors & Collaborators

  • Kymab Limited

    lead INDUSTRY

Principal Investigators

  • Jacobus Burggraaf · Centre for Human Drug Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-29
Primary Completion
2018-03-30
Completion
2018-03-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03161288 on ClinicalTrials.gov